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Purpose: To determine factors affecting the visual outcome in eyes with retinal 
vasculitis and the rate of neovascularisation relapse in ischemic vasculitis.  
 
Design:  Retrospective cohort study 
 
Methods: We reviewed 1169 uveitis patients from Moorfields Eye Hospital, UK. 
Retinal vasculitis was observed in 236 eyes (121 ischemic, 115 non- ischemic) that 
were compared to a control group (1022 eyes) with no retinal vasculitis. Ultra-
widefield fluorescein angiography images were obtained in 63 eyes with ischemic 
vasculitis to quantify area of nonperfusion measured as ischemic index.  
 
Results: The risk of vision loss was significantly more in retinal vasculitis compared 
to the non-vasculitis group (HR 1.67, C.I. 1.24 - 2.25, p=0.001). Retinal vasculitis had 
twice the risk of macular edema compared to non-vasculitis group. Macular ischemia 
increased the risk of vision loss in vasculitis eyes by 4.4 times. The use of systemic 
prednisolone in eyes with vasculitis was associated with a reduced risk of vision loss 
(HR 0.36, C.I 0.15-0.82, p=0.01). Laser photocoagulation was administered in 75 
eyes (62.0%), out of which 29 (38.1%) had new vessels relapse and required 
additional laser treatment. The median ischemic index was 25.8% (IQR 10.2 – 46%). 
Ischemia involving ≥ 2 quadrants was associated with increased risk of new vessels 
formation (HR 2.7, C.I. 1.3-5.5, p=0.003).  
 
Conclusions:  Retinal vasculitis is associated with an increased risk of vision loss, 
mainly secondary to macular ischemia, and has a higher risk of macular edema 
compared to eyes with no vasculitis. Ischemia involving ≥ 2 quadrants is a risk factor 
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Retinal vasculitis is a clinical finding in 6-15% of eyes with uveitis.1,2 It can present 
most commonly as an idiopathic condition, and sometimes in association with an 
underlying infectious or systemic disease such as Behçet's disease, sarcoidosis, 
multiple sclerosis, collagen-vascular diseases,3,4 or as an isolated ocular disease 
such as in sympathetic ophthalmia.  Retinal vasculitis presents clinically as a 
spectrum, varying from mild venous sheathing to severe obstructive vasculitis. 
Vascular damage can result in loss of vessel wall integrity, leakage of blood 
constitutes into the retinal extracellular space and development of cystoid macular 
edema (CME), a significant factor contributing to vision loss.5 Areas of retinal non-
perfusion can result in irreversible vision loss, especially when results in macular 
ischemia 6 and can induce neovascularization (NV), with its consequences such as 
recurrent vitreous hemorrhage, traction retinal detachment, rubeosis iridis, and 
neovascular glaucoma which can also lead to  permanent vision loss.5 Retinal NV 
may occur in retinal vasculitis associated with severe intraocular inflammation even 
in the absence  of retinal ischemia.7   
Treatment of retinal vasculitis depends on the underlying cause, extent of vessel 
involvement, effect on visual acuity and presence of retinal complications, such as 
retinal ischemia and NV. Treatment of inflammation includes the use of 
corticosteroids while adding other immunomodulatory therapy if needed as a steroid 
sparing agent or to provide additional therapy to control the inflammation. Laser 
photocoagulation is the mainstay in managing NV.  However, the role of retinal laser 
and anti-inflammatory medications in preventing further NV formation and ischemia 
progression has not been addressed.  
The aim of this study is to assess the clinical outcome and risk factors related to 
vision loss in retinal vasculitis, as well as the rate of progression of retinal ischemia 
and NV formation after initial management with retinal laser photocoagulation.  
Materials and Method: 
This retrospective cohort study included adult patients who attended the uveitis clinic 
of a single consultant (S.L.) at Moorfields Eye Hospital in United Kingdom between 
February 2013 and May 2016. The study received institutional review board approval 
(ethical approval for data collection: ROAD16039, visual loss in uveitis; Clinical Trials 
registry no., NCT01983488). Eyes with intermediate, posterior and panuveitis were 
included and divided into two groups based on the presence or absence of retinal 
vasculitis. Patients were considered to have retinal vasculitis according to the 
Standardization of Uveitis Nomenclature Working Group (SUN) criteria, which 
considered perivascular sheathing and vascular leakage or occlusion on fundus 
fluorescein angiography (FFA) as evidence of retinal vascular disease.8 Patient case 
notes were reviewed for any documentation of perivascular sheathing or exudates or 
intraretinal haemorrhage and had FFA showing vascular fluorescein leakage or 
occlusion which supports the diagnosis of vasculitis.2 Patients with retinal vasculitis 
were further sub-divided into ischemic retinal vasculitis (IRV) and non-ischemic 
retinal vasculitis (non-IRV). Retinal ischemia was defined as an area of 
hypofluorescence on FFA of at least one disc diameter representing retinal non-
perfusion or capillary dropout.9 Exclusion criteria for eyes with ischemic vasculitis 




































































mellitus, sickle cell disease, ocular tumour/vasoproliferative lesion, or the presence 
of extensive areas of chorioretinal scarring prior to the diagnosis of retinal ischemia. 
Best corrected visual acuity (BCVA) measured using snellen chart was collected 
from baseline and annually up to the final visit. Baseline was defined as the time of 
the first visit with a diagnosis of uveitis or, for the IRV group, time of diagnosis of 
retinal ischemia. BCVA results were converted to logarithm of the minimum angle of 
resolution (LogMAR) for analysis purposes. Vision loss was defined as BCVA ≤6/15 
according to the SUN working group criteria.8  In eyes with IRV, the incidence of NV 
formation treated with retinal laser photocoagulation and the rate of NV relapse 
requiring further laser therapy was documented. 
FFA images were either taken using a digital retinal camera system (Topcon TRC 
50IX; Topcon Medical Systems Inc, Paramus, NJ) or the ultra-wide field imaging 
(Optos PLC, Dunfermline, Scotland). For the purpose of quantifying the area of 
retinal nonperfusion, only eyes with ultra-widefield FFA were included to calculate 
the ischemic index using previously described methodology10–12. In this method, the 
total area of capillary nonperfusion seen in arteriovenous phase image was 
measured and expressed as a percentage of the total image area in pixels. This was 
done by one co-author using the manual area measurement function in ImageJ 
software (ImageJ 1.44p, National Institutes of Health, Bethesda, MD, USA). The 
central FFA images were used to measure the total image area for calculating the 
ischemic index, thus avoiding areas of peripheral distortion of the wide-field image 
owing to the spherical curvature of the eye. However, peripherally steered FFA 
images were used to determine the extent and boundaries of the peripheral 
nonperfusion. The Definition of new vessels at the optic nerve disc (NVD), new 
vessels elsewhere (NVE), and new vessels on iris (NVI) was based on FFA findings. 
Other FFA findings that were documented included the presence of macular 
ischemia, and angiographic CME. Macular ischemia was defined as a foveal 
avascular zone (FAZ) ≥ 1,000 µm at its widest diameter, or broken perifoveal 
capillary rings at the borders of the FAZ.13 Angiographic CME was defined as 
macular leakage present at 5-10 minutes post fluorescein sodium injection.  
Statistical analysis:  
Categorical variables were presented as frequencies of distribution while continuous 
variables were reported as mean and standard error (SE) except when lack of 
normality in distribution was observed for which case it was reported as median and 
interquartile range (IQR). Mann-Whitney test was used to compare continuous 
variables between two groups while Chi-square test was reserved for categorical 
variables. Repeated measurement analysis was performed using Generalized 
Estimating Equation to compare mean difference (MD) in BCVA over follow-up 
period from baseline and between groups, aiming to eliminate possible correlation 
effect between the two eyes of the same patient.  The hazard ratio (HR) and 95% 
confidence interval (C.I) for vision loss and uveitis complications were measured 
using Cox proportional hazards regression analysis. Analyses were performed with 
the SPSS statistical software (version 21, IBM, USA). A p-value of < 0.05 was 





































































In this study, 1169 case records of patients with uveitis were reviewed, among which 
retinal vasculitis was observed in 163 patients (14%). After applying the exclusion 
criteria, we compared the outcome of 142 patients (236 eyes) with retinal vasculitis 
to 584 patients (1022 eyes) with intermediate, posterior or panuveitis but no 
vasculitis.  There was no significant difference in the average follow-up time between 
the two groups [7.9 (0.58) years versus 7.8 (0.20) years, p=0.80]. The mean age at 
diagnosis was 42.5 (0.5) years in non vasculitis group and 40 (1.13) years for the 
vasculitis group (p=0.18). Male gender were slightly more predominant in the 
vasculitis group compare to the non-vasculitis one [80 patients (56.3%) versus 261 
patients (44.0%), p=0.014).  
Visual and clinical outcome of retinal vasculitis versus non-vasculitis 
The BCVA at time of diagnosis of uveitis showed no significant difference between 
the vasculitis group compared with non-vasculitis one, both with a median of 0.18 
LogMAR and IQR of 0.00 to 0.48 LogMAR (p= 0.52). In eyes with retinal vasculitis, 
the mean change in BCVA from first measure at baseline did not show a significant 
difference at one year (-0.08, SE0.03, p=0.05), five years (-0.07, SE 0.04, p=0.06) 
and ten years (-0.10, SE 0.05, p=0.05) follow-up period. The risk of vision loss was 
significantly greater in eyes with retinal vasculitis compared to those with no 
vasculitis (HR 1.67, 95% C.I. 1.24 - 2.25, p=0.001), with the risk persisting even after 
adjusting for the presence of CME (HR 1.44, 95% C.I 1.06-1.96, p=0.018), but lost 
significance when adjusted for the presence of macular ischemia (HR 1.33, 95% C.I 
0.95-1.85, p=0.08]. Risk factors contributing to vision loss among both non-vasculitis 
and vasculitis groups are listed in Table 1. In eyes with retinal vasculitis, macular 
ischemia remained a significant factor that increased the risk of vision loss by more 
than four times even after adjusting for other associated complications (HR 4.4, 95% 
C.I 2.0-9.6, p<0.001). Eyes with retinal vasculitis had more than twice the risk of 
developing CME compared to non-vasculitis group (HR 2.2, 95% C.I 1.6-2.5, 
p=<0.001).   
Systemic prednisolone was used in the management of 168 eyes (71.2%) with 
vasculitis compared to 640 eyes (63.0%) without vasculitis with no significant 
difference between the two groups (HR 1.06, 95% C.I 0.8-1.2, p=0.49). 
Immunosupressants were used in the management of 69 eyes (29.2%) with retinal 
vasculitis compared to 144 eyes (14.2%) with no vasculitis. Eyes with retinal 
vasculitis were twice as likely to require 2nd line immunosupressants when compared 
to non-vasculitis eyes (HR 2.0, 95% C.I 1.5-2.7, p=<0.001). 
Ischemic retinal vasculitis compared to non-ischemic vasculitis 
Among the 142 patients (236 eyes) with retinal vasculitis, 65 patients (115 eyes) had 
non-IRV, while 77 patients (121 eyes) had IRV. There were no major differences in 
baseline characteristics between the two groups apart from the mean follow-up time 
which was longer for the non-IRV group (7.7 versus 4.4 years, p=<0.001) (Table 2).  
Changes in BCVA from baseline in eyes IRV were statistically significant over one 
year (-0.13, SE 0.03, p<0.001), five years (-0.14, SE 0.04, p=0.001) and ten years   
(-0.16, SE 0.04, p=0.001) follow-up period, unlike eyes with non-IRV in which 
changes in BCVA overtime were not significantly different from baseline. Vision loss 
occurred in 29 (23.0%) eyes with IRV and 29 (25.2%) of eyes with non-IRV. Over 




































































IRV (HR 1.84, 95% C.I.1.07- 3.17, p=0.027). When looking at the two most common 
aetiological groups, there was no significant difference in the risk of vision loss 
between IRV and non-IRV among patients with idiopathic vasculitis (HR 1.04, p= 
0.93) as well as patients with Behcets disease (HR 2.2, p= 0.34). The median time 
for the onset of vision loss in eyes with ischemia was 0.2 years (IQR 0 to 2.7 years) 
compared to non-IRV which had a median onset of vision loss of 1 year (IQR 0 to 5.5 
years). The risk of developing CME was significantly greater among eyes with IRV 
compared to non-IRV group (HR 2.0, C.I 1.3-3.1, p<0.001).  
The risk factors contributing to vision loss in eyes with IRV and non-IRV are 
presented in Table 3. CME in eyes with IRV was 2.5 times more likely to cause vision 
loss after adjusting for the presence of macular ischemia and use of systemic 
prednisolone (HR 2.5, 95% C.I 1.8-5.7, p=0.03). Macular ischemia was observed in 
19 eyes (15.7%) with IRV, all of which were diagnosed at the initial presentation with 
ischemic vasculitis with no incidence during the follow-up period. Macular ischemia 
increased the risk of visual loss by 9.2 times (p<0.001). The use of systemic 
corticosteroids had a protective effect in preventing visual loss even after adjusting 
for the presence of macular ischemia and CME (HR 0.33, 95% C.I 0.14 – 0.77, 
p=0.01). 
Characteristics of the retinal ischemia among the studied group 
Retinal ischemia was already established during first visit with uveitis in 70 eyes 
(57.8%). In the remaining 51 eyes, ischemia occurred at a median of 7 years (IQR 
2.0 – 9.3 years) following the diagnosis of uveitis. The area of ischemia was 
localised to the peripheral area in 45 eyes (37.2%), extended to the midperipheral 
area in 45 eyes (37.2%), and involved the posterior pole in 31 eyes (25.6%). The 
area of retinal ischemia was measured in 63 eyes with ultra-widefield FFA. The 
median ischemic index was 25.8% (IQR 10.2 – 46%). 
 
Established complications of retinal ischemia included vitreous hemorrhage in 26 
eyes (21.5%), NVD in 18 (14.9%), NVE in 75 (62.0%), and NVI in 4 eyes (3.3%). 
Retinal laser photocoagulation was administered in 75 eyes (62.0%), out of which 29 
eyes (38.1%) had NV relapse and required an additional laser treatment (14 for 
treating NV at a new location and 15 for NV that failed to respond to the initial laser 
therapy). The first retinal laser photocoagulation was given at a median of 5 months 
(IQR 1-12) from baseline, ranging from 0 to 179 months post diagnosis of ischemia. 
The additional laser given for NV relapse was given at a median of 10.5 months (IQR 
7.75 – 23.5) from the initial laser, ranging from 5 to 76 months. The time between 
uveitis diagnosis and first laser treatment was not significantly different in eyes with 
NV relapse post first laser versus those with no NV relapse (Median 5.0 months for 
both groups, p=0.31 Mann-Whitney test). Ischemia involving ≥2 quadrants was 
associated with an increased risk of NV formation (HR 2.7, C.I. 1.3-5.5, p=0.003) but 







































































In this study, we examined the impact of retinal vasculitis on vision loss, as well as 
the progression of IRV. We found that (1) Vasculitis eyes were more likely to develop 
vision loss than eyes without vasculitis, mainly secondary to macular ischemia. (2) 
Eyes with retinal vasculitis had more than twice the risk of CME compared to non-
vasculitis. (3) Eyes with IRV had greater risk of vision loss than eyes with non-IRV, 
mainly secondary to macular ischemia and CME. 4) Systemic corticosteroids were 
an important protective factor, reducing the risk of vision loss in both IRV and non-
IRV eyes. (5) Retinal ischaemia involving two or more quadrants of the retina is 
significantly correlated with the initial NV formation.  
Eyes with vasculitis had significantly worse visual outcome compared to the non-
vasculitis eyes, and this was mainly related to the presence of macular ischemia in 
the vasculitis cases. A study examining 53 patients with idiopathic retinal vasculitis 
found severe vision loss to occur more often in eyes with ischemic vasculitis (34%) 
compared to the non-ischemic group (6%).14 In our study cohort, macular ischemia 
and CME were related to vision loss, suggesting a direct involvement in ocular 
morbidity among eyes with vasculitis. This finding was consistent with the results 
observed in a recent study on 82 eyes with vasculitis in which poor visual acuity was 
independently associated with central macular thickness and the size of foveal 
avascular zone.15  The increased risk of CME in the IRV compared to the non-IRV 
group in our study was also observed in a previous study 16 which suggests that 
additional factors apart from inflammation are involved in producing CME in eyes 
with IRV and that areas of nonperfusion may also promote the release of elevated 
levels of vascular endothelial growth factor (VEGF) leading to increased vascular 
permeability and development of CME, as seen in cases of diabetic retinopathy and 
retinal vein occlusion.10 We should also consider the additional risk of panretinal 
photocoagulation itself in inducing CME and thus increasing its prevalence among 
eyes with IRV.17   
Most of the eyes with retinal ischemia received their initial laser treatment within the 
first year following the diagnosis of ischemia, suggesting the need to closely observe 
ischemic retina during this period for the development of NV. Among eyes with IRV 
that underwent laser treatment, 38.1% required more than one session of laser 
photocoagulation. The rate of receiving additional laser therapy in our cohort was 
similar to that observed in a study on Eales’ disease in which 47% of eyes that 
underwent laser therapy required additional retinal laser photocoagulation.18  The 
need for additional laser therapy in our study did not reflect an increased risk of 
vision loss. The study found that retinal ischaemia involving ≥2 quadrants can 
significantly increase the risk of NV formation. This is similar to a study on IRVAN 
cases  which suggested using laser photocoagulation in eyes with retinal ischaemia 
even before NV is formed when there is more than two quadrants affected with 
capillary non-perfusion.20 
In our cohort, the use of corticosteroids was associated with a reduced risk of vision 
loss, including eyes with IRV and non-IRV.  The use of corticosteroids and other anti-
inflammatory medications in managing vasculitis and some of its associated 
complications, such as CME, contributes to their role in preventing vision loss19. 
Interestingly, macular ischemia developed early in the diagnosis of IRV, with no 




































































immunosuppressant medications in preventing macular ischemia should be 
addressed in future studies. However, we did not find a significant role for 
immunosuppressant medications in preventing ischemic relapse and NV formation.   
The study has a number of limitations related to its retrospective nature and the 
selection of patients with heterogeneous underlying diseases. However, the common 
clinical presentation of retinal vasculitis and its functional consequences, suggest 
that the outcome of these conditions can be collated and examined together. 
Furthermore, retinal ischemia is an uncommon occurrence in conditions associated 
with retinal vasculitis and this paper represents a unique opportunity to examine the 
long-term visual outcome of eyes with ischemic vasculitis and the rate of progression 
of NV formation following laser therapy and immunosuppressive treatment.  Another 
limitation was associated with the use of Optos FFA images in measuring the 
peripheral area of ischaemia. Due to the spherical curvature of the eye, ultra-
widefield images commonly associated with blurred areas within the far periphery 
when the central portion of the image is in focus. When we excluded these blurred 
far peripheral areas, the total area measured is slightly smaller than the 200 degree 
achieved by the ellipsoidal mirror within the Optos imaging system. 
In conclusion, the long term visual outcome in eyes with retinal vasculitis is worse 
when compared to eyes without vasculitis, mainly due to the risk of macular 
ischemia. The control of vasculitis with the use of systemic immunosuppressant and 
specifically systemic corticosteroids is an essential part in vasculitis management as 
it provides long-term protection by preventing further deterioration in visual function. 
It is also recommended to apply laser photocoagulation when ≥ 2 quadrants of retina 
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Table 1 Risk factors for vision loss in eyes with vasculitis compared to non-
vasculitis 
 










Crude                     Adjusted 
Vasculitis 
Crude             Adjusted 
HR (CI) P value HR (CI) 
P 
value 




0.10 - - 
2.6 
(0.9-7.5) 


























0.21 - - 
1.1 
(0.50-2.4) 









(0.6 – 3.0) 
0.36 - - 








(0.3 – 5.7) 















































































0.80 - - 
Table 1




 77 patients, 
121 eyes 
Non Ischemic  




Age, years; median (IQR) 37.7 (29 - 48) 40.5 (28 - 52) 0.82 
Follow up, years; median (IQR) 4.4 (1.4 – 8.9) 7.7 (3.8 - 11.7) <0.001 
Male; n (%) 47 (61.0) 33 (55.8) 0.23 
BCVA at baseline Median (IQR), 
LogMAR 
0.18 (0.00-0.60) 0.18 (0.00-0.48) 0.28 
BCVA at last follow up visit 
Median (IQR), LogMAR 
0.18 (0.00-0.30) 0.18 (0.00-0.48) 0.52 
Uveitis classification; n eyes (%)    
 IU 31 (25.6) 52 (45.2) 






Etiology of uveitis; n eyes (%)   - 
 Idiopathic  44 (38.0) 59 (51.0)  
 Tuberculosis 
hypersensitivity  
22 (19.0) 17 (15.0)  
 SLE 11(9.0) -  
 Behcet’s  syndrome 15 (13.0) 17 (15.0)  
 Sarcoidosis 8 (7.0) 12 (10.0)  
 ANCA positive  3 (2.4) 3 (2.0)  
 Antiphospholipid syndrome  2 (2.0) -  
 Multiple sclerosis 2 (2.0) 4 (3.0)  
 Leukocytoclastic vasculitis 2 (2.0) -  
 Dermatomyositis  2 (2.0) -  
 Takayasu arteritis 2 (2.0) 1 (1.0)  
 Syphilis/VZV 1 (0.8) 2 (2.0)  
 Rheumatoid arthritis  1 (0.8) 1 (1.0)  
N, number; IQR, Interquantile range; LogMAR, Logarithm of the minimum angle of resolution; IU, 
Intermediate uveitis; PU, Posterior uveitis; PANU, Panuveitis; ANCA, Antinuclear cytoplasmic 
antibodies. HIV, Human immune deficiency virus, HZV, Herpes zoster virus. 
* The p-value was calculated using Mann-Whitney test for continuous variables and Pearson Chi-










Table 3 Risk factors for vision loss in ischemic and non-ischemic vasculitis 
 












       Crude                    Adjusted 
Non-IRV  
      Crude                 Adjusted 




0.47 - - 
1.38 
(0.6-3.2) 
0.46 - - 
Macular edema 
1.40 















0.49 - - 
6.8 
(1.5-29.5) 





























(0.6 – 3.3) 
0.30 - - - - - - 
NV 
0.95 
(0.4 – 2.3) 




















(0.5 – 2.2) 
0.89 - - 
1.01 
(0.40-2.5) 






Table 4 Risk of neovascularization following diagnosis of retinal ischemia and 





requiring first laser 
photocoagulation 
Relapse requiring second 
laser photocoagulation 
HR (CI) P value HR (CI) P value 
Infectious versus 
non-infectious uveitis 
1.4 (0.86 – 2.53) 0.15 1.54(0.54-4.5) 0.40 
Ischemic index 
0.99 ( 0.98 – 
1.01) 
0.78 
1.01 (0.98 – 
1.04) 
0.26 
Peripheral ischemia versus 
- Midperipheral 
- Posterior pole 
 
0.98 (0.40 – 2.3) 











Ischemia involving ≥2 
quadrants 
2.70 (1.3 – 5.5) 0.003 
0.81 (0.27 – 
2.39) 
0.7 
Active uveitis at time of 
neovascularisation 
diagnosis 
1.42 (0.83-2.41) 0.19 
0.80 (0.26 – 
2.47) 
0.70 
On systemic                         
anti-inflammatory 
medications at time of 
neovascularisation 
diagnosis 
1.13 (0.67-1.91) 0.62 
1.56 (0.48 – 
4.99) 
0.43 
HR, Hazard ratio; CI, Confidence Interval 
 
Table 4
Table of content statement 
 
Manuscript No: AJO-16-1631  
Manuscript title: “Clinical outcome of retinal vasculitis and predictors for prognosis of 
ischemic retinal vasculitis 
 
Comparison of clinical outcomes between eyes with retinal vasculitis and non- 
vasculitis found that the risks of vision loss and macular edema were worse in the 
vasculitis group. The rate of new vessels relapse in ischemic retinal vasculitis 
following first laser photocoagulation was 38.1%.  The study also recommended to 
apply laser photocoagulation when ≥ 2 quadrants of retina are affected by capillary 
non-perfusion as this group carries a higher risk of new vessels formation. 
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